VivoSeq
Dermatology

Hyperpigmentation

0

Pipeline Programs

1

Active Trials

1

Companies Involved

Hyperpigmentation is an early-stage landscape with 0 programs across 1 company. The most active players are Kenvue Brands.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

15/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

13

clinical trials

Completed9 · 69%
Withdrawn2 · 15%
Unknown status1 · 8%
Recruiting1 · 8%

Trial Activity

13 trials

Tranexamic Acid vs Fractional CO2 Laser in Post-acne Hyperpigmentation
Unknown status··N/A·NCT03765021·25 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)